NRx Pharmaceuticals Inc. (NRXP)
2.02
-0.25 (-11.01%)
At close: Mar 03, 2025, 3:59 PM
2.13
5.45%
After-hours: Mar 03, 2025, 04:19 PM EST
No 1D chart data available
| Bid | 2.03 |
| Market Cap | 34.17M |
| Revenue (ttm) | 12.33K |
| Net Income (ttm) | -31.42M |
| EPS (ttm) | -2.11 |
| PE Ratio (ttm) | -0.96 |
| Forward PE | -118.33 |
| Analyst | Buy |
| Ask | 2.15 |
| Volume | 460,148 |
| Avg. Volume (20D) | 1,246,396 |
| Open | 2.35 |
| Previous Close | 2.27 |
| Day's Range | 1.87 - 2.35 |
| 52-Week Range | 1.10 - 7.33 |
| Beta | 1.12 |
About NRXP
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal...
Industry Biotechnology
Sector Healthcare
IPO Date Dec 4, 2017
Employees 2
Stock Exchange NASDAQ
Ticker Symbol NRXP
Website https://www.nrxpharma.com
Analyst Forecast
According to 4 analyst ratings, the average rating for NRXP stock is "Buy." The 12-month stock price forecast is $31, which is an increase of 1434.65% from the latest price.
Buy 75.00%
Hold 0.00%
Sell 0.00%
1 month ago
+24.56%
NRx Pharmaceuticals shares are trading higher afte...
Unlock content with
Pro Subscription
1 month ago
+30.48%
NRX Pharmaceuticals shares are trading higher after the company announced it will acquire Dura Medical with HOPE Therapeutics. Additionally, the company signed a binding term sheet with HOPE with $27 million to fund further acquisitions and pharmaceutical operations.
